Abstract: The invention relates to a process for preparing a shaped Cu—Al catalyst body for the hydrogenation of organic compounds containing a carbonyl function. More particularly, the shaped catalyst body is suitable for the hydrogenation of aldehydes, ketones and of carboxylic acids or esters thereof, specifically of fatty acids or esters thereof, such as fatty acid methyl esters, to the corresponding alcohols such as butanediol. The present invention further relates to Cu—Al catalysts obtainable by the preparation process.

Abstract: The invention relates to a catalyst molded body, which is produced by deforming a mixture of a metal oxide and a special graphite. The invention further relates to a method for producing the corresponding catalyst molded bodies and to the use of the catalyst molded bodies for catalytic reactions in which hydrogen acts as a reaction reactant or reaction product, in particular hydrogenation, hydrogenolysis, and dehydrogenation reactions. The catalysts are characterized by an improvement in the activity and selectivity in particular in hydrogenation, hydrogenolysis, and dehydrogenation reactions, said improvement being achieved by adding special graphites.

Abstract: A method for producing a shaped Cu—Zn catalyst for hydrogenating organic compounds containing a carbonyl function. The shaped catalyst is suitable for hydrogenating aldehydes, ketones and also carboxylic acids and/or their esters, fatty acids and/or their esters, such as fatty acid methyl esters, to the corresponding alcohols, dicarboxylic anhydrides, such as maleic anhydride (MAn), or esters of diacids to dialcohols, such as butanediol. The present invention further relates to Cu—Zn catalysts obtainable by the production method.

Abstract: The invention relates to a process for preparing a shaped Cu—Al catalyst body for the hydrogenation of organic compounds containing a carbonyl function. More particularly, the shaped catalyst body is suitable for the hydrogenation of aldehydes, ketones and of carboxylic acids or esters thereof, specifically of fatty acids or esters thereof, such as fatty acid methyl esters, to the corresponding alcohols such as butanediol. The present invention further relates to Cu—Al catalysts obtainable by the preparation process.

Abstract: The invention relates to a process for preparing a shaped Cu—Al catalyst body for the hydrogenation of organic compounds containing a carbonyl function. More particularly, the shaped catalyst body is suitable for the hydrogenation of aldehydes, ketones and of carboxylic acids or esters thereof, specifically of fatty acids or esters thereof, such as fatty acid methyl esters, to the corresponding alcohols such as butanediol. The present invention further relates to Cu—Al catalysts obtainable by the preparation process.

Abstract: The present invention relates to ethynyl derivatives as metabotropic glutamate receptor antagonists (negative allosteric modulators) for use in the treatment of, e.g., anxiety and pain, depression, Fragile-X syndrome, autism spectrum disorders, Parkinson's disease, and gastroesophageal reflux disease (GERD).

Abstract: The present invention relates to ethynyl derivatives as metabotropic glutamate receptor antagonists (negative allosteric modulators) for use in the treatment of, e.g., anxiety and pain, depression, Fragile-X syndrome, autism spectrum disorders, Parkinson's disease, and gastroesophageal reflux disease (GERD).

Abstract: The present invention relates to ethynyl derivatives as metabotropic glutamate receptor antagonists (negative allosteric modulators) for use in the treatment of, e.g., anxiety and pain, depression, Fragile-X syndrome, autism spectrum disorders, Parkinson's disease, and gastroesophageal reflux disease (GERD).

Abstract: A method for producing a shaped Cu—Zn catalyst for hydrogenating organic compounds containing a carbonyl function. The shaped catalyst is suitable for hydrogenating aldehydes, ketones and also carboxylic acids and/or their esters, fatty acids and/or their esters, such as fatty acid methyl esters, to the corresponding alcohols, dicarboxylic anhydrides, such as maleic anhydride (MAn), or esters of diacids to dialcohols, such as butanediol. The present invention further relates to Cu—Zn catalysts obtainable by the production method.

Abstract: The present invention relates to ethynyl derivatives of formula I wherein Y is N or CH R1 is fluoro or chloro or to a pharmaceutically acceptable acid addition salt, to a racemic mixture, or to its corresponding enantiomer and/or optical isomer and/or stereoisomer thereof. It has now surprisingly been found that the compounds of general formula I are metabotropic glutamate receptor antagonists (negative allosteric modulators) for use in the treatment of anxiety and pain, depression, Fragile-X syndrom, autism spectrum disorders, Parkinson's disease, and gastroesophageal reflux disease (GERD).

Abstract: The present invention relates to ethynyl derivatives as metabotropic glutamate receptor antagonists (negative allosteric modulators) for use in the treatment of, e.g., anxiety and pain, depression, Fragile-X syndrome, autism spectrum disorders, Parkinson's disease, and gastroesophageal reflux disease (GERD).

Abstract: The present invention relates to ethynyl derivatives of formula I wherein Y is N or CH or to a pharmaceutically acceptable acid addition salt, to a racemic mixture, or to its corresponding enantiomer and/or optical isomer and/or stereoisomer thereof.

Abstract: The present invention relates to ethynyl derivatives of formula I wherein R1 is phenyl, which is optionally substituted by 1-2 halogen atoms; selected from fluorine or chlorine; or to a pharmaceutically acceptable acid addition salt in enantiomerically pure form. It has been found that the compounds of general formula I are allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGluR5).

Abstract: The present invention relates to ethynyl compounds of formula I-C1 wherein R1, R2, R2?, R3, R3?, R6, U, V and W are as defined herein and to a pharmaceutically acceptable acid addition salts, to a racemic mixtures, or to its corresponding enantiomers and/or optical isomers and/or stereoisomers thereof, which are allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGluR5).

Abstract: The present invention relates to ethynyl derivatives of formula I wherein R1 is phenyl, which is optionally substituted by 1-2 halogen atoms; selected from fluorine or chlorine; or to a pharmaceutically acceptable acid addition salt in enantiomerically pure form. It has been found that the compounds of general formula I are allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGluR5).

Abstract: The present invention relates to ethynyl derivatives of formula I wherein Y is N or CH R1 is fluoro or chloro R2 is hydrogen or methyl or to a pharmaceutically acceptable acid addition salt, to a racemic mixture, or to its corresponding enantiomer and/or optical isomer and/or stereoisomer thereof. It has now surprisingly been found that the compounds of general formula I are metabotropic glutamate receptor antagonists (negative allosteric modulators) for use in the treatment of anxiety and pain, depression, Fragile-X syndrome, autism spectrum disorders, Parkinson's disease, and gastroesophageal reflux disease (GERD).

Abstract: The present invention relates to ethynyl derivatives of formula I wherein R1 is phenyl, 3-fluorophenyl, 4-fluorophenyl or 2,5-di-fluorophenyl; or to a pharmaceutically acceptable acid addition salt, in enantiomerically pure form with the absolute configuration as shown in formula I. It has now surprisingly been found that the compounds of general formula I are allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGluR5) which show advantageous biochemical-, physicochemical- and pharmacodynamic-properties compared to compounds of prior art.

Abstract: The present invention relates to ethynyl derivatives of formula I X, G, R1, R2, R3, R3?, R4, R4?, R5, R6, R6?, m, and n are as defined herein or to a pharmaceutically acceptable acid addition salt, to a racemic mixture, or to its corresponding enantiomer and/or optical isomer and/or stereoisomer thereof. Compounds of formula I are positive allosteric modulators (PAM) of the metabotropic glutamate receptor subtype 5 (mGluR5). They can be used for the treatment of schizophrenia or cognitive disorders.

Abstract: The present invention relates to ethynyl derivatives of formula I wherein R1 is hydrogen or halogen; R2 is C1-3-alkyl or —(CH2)n—O—CH3; n is 2 or 3; m is 1 or 2; or to a pharmaceutically acceptable acid addition salt, to a racemic mixture, or to its corresponding enantiomer and/or optical isomer and/or stereoisomer thereof. It has been found that the compounds of general formula I are allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGluR5) with improved properties for the treatment of schizophrenia, cognitive diseases, fragile X syndrome or autism.

Abstract: The invention relates to a process for preparing a shaped Cu—Al catalyst body for the hydrogenation of organic compounds containing a carbonyl function. More particularly, the shaped catalyst body is suitable for the hydrogenation of aldehydes, ketones and of carboxylic acids or esters thereof, specifically of fatty acids or esters thereof, such as fatty acid methyl esters, to the corresponding alcohols such as butanediol. The present invention further relates to Cu—Al catalysts obtainable by the preparation process.